Default company panoramic image
163a0330 4924 48a3 8afd 98b994e8f317


We are developing ultra sensitive, quantitative POC diagnostic platforms and novel disease specific diagnostic tests

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Durham, NC, USA
  • Currency USD
  • Founded January 2006
  • Employees 5
  • Website

Company Summary

Clinical standards for several market segments, especially the $2B CV POC diagnostic segment, are moving to defined “high sensitivity” standards which are beyond current POC platforms capabilities. Our next generation POC platforms will meet these “high sensitivity” standards and provide central lab level sensitivity and reliability. Our novel tests for acetaminophen overdose and Sickle Cell Disease have market potentials exceeding $100M each.


  • Default avatar
    Frank Wang

    Dr. Wang obtained his Ph.D. in Applied Physics from Osaka University, Japan. Dr. Wang is also a co-founder and currently the Chairman of North Carolina Chinese Business Association. Dr. Wang was previously founder and President of BioMachines, Inc. Dr. Wang worked as an Assistant Professor at UNC where he published on Biophysics and Bioengineering research areas.


  • Default avatar
    Williams Mullen

Previous Investors

  • Default avatar